WuXi Biologics announces to make an investment of US$382 million to construct a largest Biomanufacturing facility centre in Ireland using single-use biologics approach.
The Biomanufacturing facility centre is proposed to get constructed on the 26-hectare campus of WuXi Biologics in Ireland.
The expansion plan is expected to create nearly 400 highly skilled new jobs over a period of five years in the area of biologics as well as approximately other 700 construction jobs.
This plant is going to be the world’s largest Biomanufacturing facility plant which will significantly utilise single-use bioreactors with an overall installed capacity of 48,000 L fed-batch and 6,000 L perfusion bioreactor.
The new state-of-the-art next-gen biomanufacturing facility will ensure the highest quality manufacturing of biologics with a robust supply chain to benefit patients globally.
The other companies which are going to partner with WuXi Biologics in the construction of Biomanufacturing facility centre are IDA, ISIF, and WuXi AppTec Group.
|US$ 382 million
|WuXi Biologics, IDA, ISIS & WuXi AppTech Group